Alessandro Affronti

Dr. Alessandro Affronti

Cardiac Surgery, Azienda Ospedaliera di Perugia, Perugia, Umbria, Italy
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Journal of Cardiothoracic and Vascular Anesthesia
Verified
Journal Article
Closed access
Alessandro AffrontiAlessandro Affronti
Alessandro Affronti
FCFrancesco Casali
Francesco Casali
PEPaolo Eusebi
Paolo Eusebi
CTCristina Todisco
Cristina Todisco
FVFrancesca Volpi
Francesca Volpi
TRTemistocle Ragni
Temistocle Ragni

26 September 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Alessandro AffrontiAlessandro Affronti
Alessandro Affronti
RPRobert Pruna-Guillen
Robert Pruna-Guillen
ESElena Sandoval
Elena Sandoval
DPDaniel Pereda
Daniel Pereda
JAJorge Alcocer
Jorge Alcocer
Eduard QuintanaEduard Quintana
Eduard Quintana
Hypertrophic cardiomyopathy (HCM) is a complex, underestimated, multifaceted disease frequently associated with left ventricular outflow tract (LVOT) obstruction. It is clearly demonstrated that this is due not only to septal hypertrophy but also to systolic anterior motion (SAM) of mitral valve leaflets secondary to mitral valve/subvalvular apparatus abnormalities. Surgical treatment involves performing an extended septal myectomy, eventually followed by ancillary procedures to those structures responsible for maintaining LVOT obstruction, if necessary. In this review, we describe the spectrum of possible surgical techniques beyond septal myectomy and their pathophysiologic rationale.

8 August 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
RPRobert Pruna-Guillen
Robert Pruna-Guillen
DPDaniel Pereda
Daniel Pereda
MCManuel Castellà
Manuel Castellà
ESElena Sandoval
Elena Sandoval
Alessandro AffrontiAlessandro Affronti
Alessandro Affronti
Eduard QuintanaEduard Quintana
Eduard Quintana
Introduction and objectives: Septal myectomy remains the first septal reduction therapy for hypertrophic obstructive cardiomyopathy in young patients and those requiring concomitant procedures. Its role in advanced ages is questioned due to perceived increased risk. We assess the outcomes of surgical relief of obstruction in patients beyond 65 years old. Methods: A single-center retrospective review of patients ≥ 65 years old undergoing septal myectomy through median sternotomy between April 2015 and February 2020. Results: We identified 52 patients. Mean age was 71.8 ± 4.9 years; 36 (69.2%) were females. All were symptomatic. Mean highest LVOT gradient was 90 ± 39 mmHg. All patients had systolic anterior motion (SAM) of the mitral valve and 36 (69.2%) ≥ moderate mitral regurgitation. Additional LVOT interventions beyond myectomy were performed in 34 (65.4%). At least one other cardiac concomitant procedure was performed 44 (84.6%). No perioperative mortality in elective surgery occurred. One patient (1.9%) developed atrio-ventricular block. Postoperative mean gradient was 4.3 ± 1.9 mmHg, with 46 (88.4%) achieving complete resolution of obstruction. Mitral regurgitation was reduced to grade ≤ I in 46 (88.5%). Mean follow-up time was 2.3 ± 1.2 years and 82% of patients were in NYHA I. Survival at 2 years was 98%. Conclusion: Septal myectomy in the elderly is a safe and effective operation despite the need for concomitant procedures. LVOT interventions beyond septal myectomy to relieve obstruction are common in this advanced cohort of hypertrophic cardiomyopathy patients. This operation carried at experienced centers seems an unmatched therapeutic option.

25 August 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
IAIñigo Anduaga
Iñigo Anduaga
Alessandro AffrontiAlessandro Affronti
Alessandro Affronti
PCPedro Luis Cepas-Guillen
Pedro Luis Cepas-Guillen
JAJorge Alcocer
Jorge Alcocer
EFEduardo Flores-Umanzor
Eduardo Flores-Umanzor
XFXavier Freixa
Xavier Freixa
Atrial fibrillation (AF) is the most common arrhythmia worldwide. It is associated with increased mortality and morbidity, especially due to the increased risk of ischemic stroke and systemic embolism in these patients. For this reason, thromboembolism prevention is the cornerstone of managing AF, and oral anticoagulation is nowadays the first-line treatment. However, since most thrombi form in the left atrial appendage and anticoagulant therapy may have side effects and be contraindicated in some patients, surgical and percutaneous left atrial appendage occlusion (LAAO) have emerged as a non-pharmacological alternative. This review summarizes all existing evidence on surgical and percutaneous LAAO.

1 November 2019 in Current Opinion in Cardiology
Verified
Journal Article
Closed access
Alessandro AffrontiAlessandro Affronti
Alessandro Affronti
MRMarc Ruel
Marc Ruel
MGMario F.L. Gaudino
Mario F.L. Gaudino
Purpose of review The debate on the second best conduit for CABG is still intense. In this review, we discuss the role of the radial artery and the right internal thoracic artery (RITA) compared with saphenous vein grafts (SVG). Recent findings The recent RADIAL STUDY has been the first evidence based on randomized trials of a clinical benefit using a second arterial graft in CABG. On the other hand, the definitive 10-year results of the ART trial failed to show a clinical advantage associated with the use of bilateral internal thoracic artery (BITA). A thorough and contextualized analysis of this and other studies, however, may offer a different perspective. Arterial conduits in CABG have shown better patency rates than SVG. Whether this leads to better clinical outcomes is still debated. In this setting, the radial artery and the RITA seem to offer a similar advantage, although with different indications and contraindications.

8 June 2022 in Asian Cardiovascular and Thoracic Annals
Verified
Journal Article
Closed access
CTCorrado Tramontin
Corrado Tramontin
Alessandro AffrontiAlessandro Affronti
Alessandro Affronti
ECEmiliano Maria Cirio
Emiliano Maria Cirio
Outflow graft obstruction is a potentially catastrophic complication of left ventricular assist devices that may occur secondary to different mechanisms. Two cases of Heartmate 3 outflow graft obstruction associated with two different pathophysiological mechanisms are presented. The first one was a 70-year-old man who developed outflow graft obstruction secondary to kinking. The second case was a 72-year-old man who presented with signs and symptoms of heart failure due to outflow graft extrinsic obstruction. Both cases were diagnosed with 3D-CT scan and successfully surgically treated.